ADMA Biologics, Inc. (ADMA) Stock AnalysisADMAStock AnalysisADMA Biologics, Inc.

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ADMA Biologics is currently priced at $9.34, which is significantly below its analyst price target of $18 from Canaccord, indicating potential upside. However, the RSI is at 38.24, suggesting the stock is nearing oversold conditions, which could signal a rebound. The recent 5-day change is down 5.08%, reflecting short-term weakness, but the company has shown strong revenue growth with Q2 revenue at $124.4 million, a 2% year-over-year increase. The main risk is the declining analyst sentiment, with Mizuho downgrading its price target to $17 from $20, which could pressure the stock further in the short term.

4 analysts cover ADMA: 4 rate it Buy, 0 Hold and 0 Sell.